Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine · 11.01.2024 · 390 (2) · 118-131
DOI: 10.1056/nejmoa2302299 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 11.01.2024. Verfasst von Alexander Drilon und 33 weiteren Autor:innen. Beteiligte Einrichtung: From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D.) and the NYU Perlmutter Cancer Center (V.V.) - all in New York; t…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein-Tyrosine Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 254-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Manchester Biomedical Research Centre, National Cancer Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D.) and the NYU Perlmutter Cancer Center (V.V.) - all in New York; the University of Colorado, Anschutz Medical Campus, Aurora (D.R.C.); M…
Förderung
- NCI NIH HHS
- Manchester Biomedical Research Centre
- National Cancer Institute
- Bristol-Myers Squibb
Zitieren
APA
Drilon, A., Camidge, D. R., Lin, J. J., Kim, S. W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., Lee, K. H., Popat, S., Springfeld, C., Nagasaka, M., Felip, E., Yang, N., Velcheti, V., Lu, S., Kao, S., …, & TRIDENT-1 Investigators (2024). Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 390(2), 118-131. https://doi.org/10.1056/nejmoa2302299
Vancouver
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, et al. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(2):118-131. doi:10.1056/nejmoa2302299
BibTeX
@article{Drilon2024,
author = {Drilon, Alexander and Camidge, D Ross and Lin, Jessica J and Kim, Sang-We and Solomon, Benjamin J and Dziadziuszko, Rafal and Besse, Benjamin and Goto, Koichi and de Langen, Adrianus Johannes and Wolf, Jürgen and Lee, Ki Hyeong and Popat, Sanjay and Springfeld, Christoph and Nagasaka, Misako and Felip, Enriqueta and Yang, Nong and Velcheti, Vamsidhar and Lu, Shun and Kao, Steven and Dooms, Christophe and Krebs, Matthew G and Yao, Wenxiu and Beg, Muhammad Shaalan and Hu, Xiufeng and Moro-Sibilot, Denis and Cheema, Parneet and Stopatschinskaja, Shanna and Mehta, Minal and Trone, Denise and Graber, Armin and Sims, Gregory and Yuan, Yong and Cho, Byoung Chul and TRIDENT-1 Investigators, TRIDENT-1 Investigators},
title = {Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {2},
pages = {118--131},
doi = {10.1056/nejmoa2302299}
}
EUVIMED